Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
VNRX VolitionRX
2.230-0.120-5.11%
Close
02/03 16:00 ET
2.2300.0000.00%
Post Mkt Price 02/03 16:15 ET
High
2.385
Open
2.340
Turnover
422.66K
Low
2.230
Pre Close
2.350
Volume
184.95K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Benchmark Downgrades VolitionRx (NYSEAMERICAN:VNRX) to Hold
VolitionRx (NYSEAMERICAN:VNRX – Get Rating) was downgraded by stock analysts at Benchmark from a "buy" rating to a "hold" rating in a note issued to investors on Wednesday, Marketbeat reports. The an
VolitionRX Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/01/2023 — Benchmark Downgrades Buy → Hold 12/19/2022 140.35% EF Hutton → $6 Initiates Coverage On → Bu
Benchmark Downgrades VolitionRX to Hold
Benchmark analyst Bruce Jackson downgrades VolitionRX (AMEX:VNRX) from Buy to Hold.
VolitionRX Downgraded to Hold From Speculative Buy at Benchmark
VolitionRX Downgraded to Hold From Speculative Buy at Benchmark
Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on January 25, 2023
NEW YORK, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading small-capitalization equity research and conference provider, will host its Spotlight Emerging Growth Invitational Investor Conference on
Volition to Take Part in Nu.Q Vet Commercial Strategy Webinar
Sidoti's January Micro-Cap Conference
NEW YORK, NY / ACCESSWIRE / January 17, 2023 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place Wednesday and Thursda
VolitionRx: Nu.Q Vet Cancer Test Available Through Idexx Laboratories Network
Volition Announces Expansion of Availability of the Nu.Q® Vet Cancer Test Through IDEXX's Reference Laboratory Network
HENDERSON, Nev., Jan. 12, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the availability of its Nu.Q® Vet Cancer Test through the IDEXX
Volition Issues Business Review 2022
HENDERSON, Nev, Jan. 8, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has issued a Business Review of 2022, outlining its key highlights as the
Company Overview
More
VolitionRX Ltd. is a multi-national life sciences company, which engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.
CEO： Mr. Cameron John. Reynolds
Market： AMEX
Listing Date： 02/06/2015
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet